These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 26631094)

  • 21. Clinical and Structural Efficacy of Hydroxychloroquine in Rheumatoid Arthritis: A Systematic Review.
    Rempenault C; Combe B; Barnetche T; Gaujoux-Viala C; Lukas C; Morel J; Hua C
    Arthritis Care Res (Hoboken); 2020 Jan; 72(1):36-40. PubMed ID: 30629341
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: a randomized, double-blind six-week trial with eighteen-week extension.
    Furst DE; Lindsley H; Baethge B; Botstein GR; Caldwell J; Dietz F; Ettlinger R; Golden HE; McLaughlin GE; Moreland LW; Roberts WN; Rooney TW; Rothschild B; Sack M; Sebba AI; Weisman M; Welch KE; Yocum D
    Arthritis Rheum; 1999 Feb; 42(2):357-65. PubMed ID: 10025931
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chronological effects of non-steroidal anti-inflammatory drug therapy on oxidative stress and antioxidant status in patients with rheumatoid arthritis.
    Nawaz H; Ali A; Rehman T; Aslam A
    Clin Rheumatol; 2021 May; 40(5):1767-1778. PubMed ID: 33009599
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A population model of early rheumatoid arthritis disease activity during treatment with methotrexate, sulfasalazine and hydroxychloroquine.
    Wojciechowski J; Wiese MD; Proudman SM; Foster DJ; Upton RN
    Br J Clin Pharmacol; 2015 May; 79(5):777-88. PubMed ID: 25394211
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current treatment paradigms in rheumatoid arthritis.
    Fries JF
    Rheumatology (Oxford); 2000 Jun; 39 Suppl 1():30-5. PubMed ID: 11001377
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis.
    Finckh A; Bansback N; Marra CA; Anis AH; Michaud K; Lubin S; White M; Sizto S; Liang MH
    Ann Intern Med; 2009 Nov; 151(9):612-21. PubMed ID: 19884622
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advances in anti-inflammatory therapy.
    Aletaha D; Smolen JS
    Acta Med Austriaca; 2002; 29(1):1-6. PubMed ID: 11899747
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment with cyclosporin switching to hydroxychloroquine in patients with rheumatoid arthritis.
    Kim WU; Seo YI; Park SH; Lee WK; Lee SK; Paek SI; Cho CS; Song HH; Kim HY
    Ann Rheum Dis; 2001 May; 60(5):514-7. PubMed ID: 11302876
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiovascular Safety of Hydroxychloroquine in US Veterans With Rheumatoid Arthritis.
    Faselis C; Zeng-Treitler Q; Cheng Y; Kerr GS; Nashel DJ; Liappis AP; Weintrob AC; Karasik PE; Arundel C; Boehm D; Heimall MS; Connell LB; Taub DD; Shao Y; Redd DF; Sheriff HM; Zhang S; Fletcher RD; Fonarow GC; Moore HJ; Ahmed A
    Arthritis Rheumatol; 2021 Sep; 73(9):1589-1600. PubMed ID: 33973403
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis.
    Mok MY; Ng WL; Yuen MF; Wong RW; Lau CS
    Clin Exp Rheumatol; 2000; 18(3):363-8. PubMed ID: 10895374
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Drug therapy of rheumatoid arthritis].
    Arndt U; Rittmeister M; Möller B
    Orthopade; 2003 Dec; 32(12):1095-103. PubMed ID: 14655006
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Brief Report: Intensification to Triple Therapy After Treatment With Nonbiologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis in the United States From 2009 to 2014.
    Sparks JA; Krumme AA; Shrank WH; Matlin OS; Brill G; Pezalla EJ; Choudhry NK; Solomon DH
    Arthritis Rheumatol; 2016 Jul; 68(7):1588-95. PubMed ID: 26866506
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of osteoarthritis and rheumatoid arthritis: prospects and possibilities.
    Blackburn WD
    Am J Med; 1996 Feb; 100(2A):24S-30S. PubMed ID: 8604723
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis.
    Rempenault C; Combe B; Barnetche T; Gaujoux-Viala C; Lukas C; Morel J; Hua C
    Ann Rheum Dis; 2018 Jan; 77(1):98-103. PubMed ID: 28970215
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Pharmacological Mechanisms and Therapeutic Activities of Hydroxychloroquine in Rheumatic and Related Diseases.
    Hu C; Lu L; Wan JP; Wen C
    Curr Med Chem; 2017; 24(20):2241-2249. PubMed ID: 28302011
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hydroxychloroquine may be associated with reduced risk of coronary artery diseases in patients with rheumatoid arthritis: A nationwide population-based cohort study.
    Hung YM; Wang YH; Lin L; Wang PYP; Chiou JY; Wei JC
    Int J Clin Pract; 2018 May; 72(5):e13095. PubMed ID: 29691971
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs.
    Malysheva OA; Wahle M; Wagner U; Pierer M; Arnold S; Häntzschel H; Baerwald CG
    J Rheumatol; 2008 Jun; 35(6):979-85. PubMed ID: 18412314
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of rheumatoid arthritis.
    Gaffo A; Saag KG; Curtis JR
    Am J Health Syst Pharm; 2006 Dec; 63(24):2451-65. PubMed ID: 17158693
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factors associated with the initiation of biologic disease-modifying antirheumatic drugs in Texas Medicaid patients with rheumatoid arthritis.
    Kim G; Barner JC; Rascati K; Richards K
    J Manag Care Spec Pharm; 2015 May; 21(5):401-7. PubMed ID: 25943001
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors of treatment initiation with tumor necrosis factor-α inhibitors in patients with rheumatoid arthritis.
    Desai RJ; Rao JK; Hansen RA; Fang G; Maciejewski ML; Farley JF
    J Manag Care Spec Pharm; 2014 Nov; 20(11):1110-20. PubMed ID: 25351972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.